Xbrane Biopharma AB (publ)

OM:XBRANE Stock Report

Market Cap: SEK 238.6m

Xbrane Biopharma Management

Management criteria checks 3/4

Xbrane Biopharma's CEO is Martin Amark, appointed in Jan 2015, has a tenure of 9.92 years. total yearly compensation is SEK3.36M, comprised of 77% salary and 23% bonuses, including company stock and options. directly owns 0.012% of the company’s shares, worth SEK29.54K. The average tenure of the management team and the board of directors is 9.9 years and 4.6 years respectively.

Key information

Martin Amark

Chief executive officer

SEK 3.4m

Total compensation

CEO salary percentage77.0%
CEO tenure9.9yrs
CEO ownership0.01%
Management average tenure9.9yrs
Board average tenure4.6yrs

Recent management updates

Recent updates

Even With A 30% Surge, Cautious Investors Are Not Rewarding Xbrane Biopharma AB (publ)'s (STO:XBRANE) Performance Completely

Sep 30
Even With A 30% Surge, Cautious Investors Are Not Rewarding Xbrane Biopharma AB (publ)'s (STO:XBRANE) Performance Completely

Market Cool On Xbrane Biopharma AB (publ)'s (STO:XBRANE) Revenues Pushing Shares 34% Lower

Aug 05
Market Cool On Xbrane Biopharma AB (publ)'s (STO:XBRANE) Revenues Pushing Shares 34% Lower

Market Might Still Lack Some Conviction On Xbrane Biopharma AB (publ) (STO:XBRANE) Even After 32% Share Price Boost

Jun 21
Market Might Still Lack Some Conviction On Xbrane Biopharma AB (publ) (STO:XBRANE) Even After 32% Share Price Boost

Is Xbrane Biopharma (STO:XBRANE) In A Good Position To Deliver On Growth Plans?

Jun 04
Is Xbrane Biopharma (STO:XBRANE) In A Good Position To Deliver On Growth Plans?

We Think Xbrane Biopharma (STO:XBRANE) Needs To Drive Business Growth Carefully

Nov 05
We Think Xbrane Biopharma (STO:XBRANE) Needs To Drive Business Growth Carefully

Market Sentiment Around Loss-Making Xbrane Biopharma AB (publ) (STO:XBRANE)

Mar 24
Market Sentiment Around Loss-Making Xbrane Biopharma AB (publ) (STO:XBRANE)

Xbrane Biopharma AB (publ) (STO:XBRANE) Insiders Increased Their Holdings

Mar 02
Xbrane Biopharma AB (publ) (STO:XBRANE) Insiders Increased Their Holdings

Xbrane Biopharma AB (publ)'s (STO:XBRANE) Intrinsic Value Is Potentially 28% Above Its Share Price

Feb 10
Xbrane Biopharma AB (publ)'s (STO:XBRANE) Intrinsic Value Is Potentially 28% Above Its Share Price

We Think Xbrane Biopharma (STO:XBRANE) Can Afford To Drive Business Growth

Jan 12
We Think Xbrane Biopharma (STO:XBRANE) Can Afford To Drive Business Growth

CEO Compensation Analysis

How has Martin Amark's remuneration changed compared to Xbrane Biopharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-SEK 305m

Jun 30 2024n/an/a

-SEK 341m

Mar 31 2024n/an/a

-SEK 361m

Dec 31 2023SEK 3mSEK 3m

-SEK 322m

Sep 30 2023n/an/a

-SEK 285m

Jun 30 2023n/an/a

-SEK 246m

Mar 31 2023n/an/a

-SEK 189m

Dec 31 2022SEK 5mSEK 2m

-SEK 169m

Sep 30 2022n/an/a

-SEK 146m

Jun 30 2022n/an/a

-SEK 147m

Mar 31 2022n/an/a

-SEK 172m

Dec 31 2021SEK 4mSEK 2m

-SEK 183m

Sep 30 2021n/an/a

-SEK 213m

Jun 30 2021n/an/a

-SEK 219m

Mar 31 2021n/an/a

-SEK 215m

Dec 31 2020SEK 3mSEK 1m

-SEK 218m

Sep 30 2020n/an/a

-SEK 222m

Jun 30 2020n/an/a

-SEK 210m

Mar 31 2020n/an/a

-SEK 204m

Dec 31 2019SEK 2mSEK 1m

-SEK 188m

Sep 30 2019n/an/a

-SEK 154m

Jun 30 2019n/an/a

-SEK 56m

Mar 31 2019n/an/a

-SEK 40m

Dec 31 2018SEK 1mSEK 1m

-SEK 13m

Sep 30 2018n/an/a

SEK 30k

Jun 30 2018n/an/a

-SEK 69m

Mar 31 2018n/an/a

-SEK 45m

Dec 31 2017SEK 1mSEK 919k

-SEK 45m

Compensation vs Market: Martin's total compensation ($USD304.72K) is above average for companies of similar size in the Swedish market ($USD231.71K).

Compensation vs Earnings: Martin's compensation has been consistent with company performance over the past year.

CEO

Martin Amark (44 yo)

9.9yrs

Tenure

SEK 3,360,000

Compensation

Mr. Martin Amark serves as Chief Executive Officer of Xbrane Biopharma AB (publ) and served as its Head of Investor Relation since February 14, 2019. He has experience from Bain & Co as a Management Consul...

Leadership Team

NamePositionTenureCompensationOwnership
Martin Amark
Chief Executive Officer9.9yrsSEK 3.36m0.012%
SEK 29.5k
Siavash Bashiri
COO, Head of Biosimilars & Deputy CEO9.9yrsSEK 1.79m0.0076%
SEK 18.2k
Jan-Willem De Gier
Co-Founderno datano datano data
Samuel Wagner
Co-Founder & Member of Scientific Advisory Board16.9yrsno datano data
Anette Lindqvist
CFO & Head of Investor Relations3.9yrsno data0.00098%
SEK 2.3k
David Vikström
Chief Technology Officer10.9yrsno data0.0022%
SEK 5.2k
Dina Jurman
Head of Clinical Affairs7.3yrsno data0.000030%
SEK 71.6
Anders Wallström
Head of Manufacturing & Supply Chain5.9yrsno data0.00091%
SEK 2.2k
Håkan Yildirim
Head of Intellectual Propertyno datano datano data

9.9yrs

Average Tenure

45.5yo

Average Age

Experienced Management: XBRANE's management team is seasoned and experienced (9.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Samuel Wagner
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Björn Nilsson
Member of Scientific Advisory Boardno datano datano data
Mats Thoren
Independent Director4.6yrsSEK 435.00k0.00026%
SEK 620.4
Eva Nilsagard
Independent Director5.6yrsSEK 460.00k0.00026%
SEK 620.4
Gunnar Von Heijne
Member of Scientific Advisory Boardno datano datano data
Joen Luirink
Member of Scientific Advisory Boardno datano datano data
David Drew
Member of Scientific Advisory Boardno datano datano data
Kirsti Gjellan
Independent Director2.6yrsSEK 385.00k0.00016%
SEK 381.8
Anders Tullgren
Independent Chairman of the Board6.7yrsSEK 820.00k0.0046%
SEK 11.0k
Kristoffer Bissessar
Independent Directorless than a yearno datano data

4.6yrs

Average Tenure

61yo

Average Age

Experienced Board: XBRANE's board of directors are considered experienced (4.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 11:48
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Xbrane Biopharma AB (publ) is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John SavinEdison Investment Research
Hans MählerNordea Markets
null nullNordea Markets